Identifying the contribution of mTOR activity in cyclin D1 overexpression in mantle cell lymphomas highlighted the possible use of mTOR inhibitors (mTORIs) in lymphomas and other malignancies [266]. This evidence concerns the gene MTOR and lymphoma.